Which company develops and produces Apelis?

Alpelisib is developed and produced by Novartis Pharmaceuticals of Switzerland. Alpelisib is a phosphatidylinositol with potent anti-tumor activity3-kinase (PI3K) inhibitor, apelixis is indicated in combination with fulvestrant for the treatment of advanced or metastatic breast cancer in postmenopausal women and men. The cancer must be hormone receptor (HR) positive, human epidermal growth factor receptor2 (her 2) negative and PIK3CAmutated, the cancer must be tested by an FDA-approved test after progression on an endocrine-based regimen. Apelvis is also indicated for the treatment of adult and pediatric patients 2 years and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) requiring systemic therapy.

ApelixMost Common Adverse Reactions (Including Laboratory Abnormalities (All Grades, Incidence≥ 20%) including elevated blood sugar, elevated creatinine, diarrhea, rash, decreased lymphocyte count, elevated γ-glutamyl transferase (GGT), nausea, alanine aminotransferase (ALT ), fatigue, decreased hemoglobin, increased lipase, decreased appetite, stomatitis, vomiting, weight loss, decreased calcium, decreased glucose, prolonged activated partial thromboplastin time (aPTT) and hair loss. Apelixdoes not prolong the QTcF interval. > patients achieved dose-dependent benefit from the treatment, with a dose advantage of 200mg daily200mg100mgdose advantage51% and once-daily 300mgdose advantage twice daily150mgDosage advantage22%. This indicates that patients who require lower doses may benefit from twice daily dosing. If you want to get more high-quality information, you can contact YaDE, which will do its best to learn more about overseas high-quality drugs.